---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000164"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:14:14.497955+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis repurchases 7.5M shares from Matrix at $1.33 each; director resigns

## Summary
- Repurchased 7,500,000 shares from Matrix Capital Master Fund at $1.33/share, a 5% discount to the Dec 12 close of $1.40.
- Repurchase closed on December 15, 2025; funded by existing cash, with no material impact on projected cash runway into late 2027.
- Director Karan Takhar (Matrix Capital) resigned immediately, reducing board size from 7 to 6; resignation not due to any disagreement.
- Matrix's sale is part of its previously announced 2024 plan to wind down its family of funds.

## SEC filing metadata
- accession: 0001725160-25-000164
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000164/0001725160-25-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000164/zntl-20251215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000164
- JSON: https://secwatch.observer/filing/0001725160-25-000164.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.